June, 2026
Why cell and gene therapy trials demand a different level of execution in clinical trial logistics
Cell and gene therapy (CGT) is changing the rules of clinical development — and execution is where that change is felt most.
Unlike traditional models, where products can be manufactured in advance and distributed at scale, CGT introduces a fundamentally different operating environment. Treatments are often patient-specific, highly time-sensitive, and dependent on complex global coordination.
As a result, clinical trial logistics, CGT supply chain management, clinical trial supply chain coordination, and regulatory alignment are no longer supporting functions. They are central to whether a therapy can be delivered — and whether a clinical trial can proceed.
So what makes execution in CGT so different?
Why traditional clinical trial models don't translate to CGT
Traditional clinical trial supply chain models are built around predictability. Manufacturing, storage, and pharmaceutical distribution can be planned in advance. Timelines are designed to absorb disruption.
In CGT, those assumptions no longer hold.
Many cell and gene therapy companies are working with:
- Individualized therapies rather than batch production
- Time-critical delivery windows
- Complex, multi-country supply chains
- Strict clinical trial compliance and regulatory requirements
This creates a system where execution must operate with far greater precision — and far less tolerance for disruption.
Patient-specific pathways change the clinical trial supply chain
In many CGT trials, each therapy is unique to the individual patient. This means the clinical trial supply chain is triggered by that patient’s treatment pathway — not by forecast demand.
Materials must be:
- Collected from the patient
- Transported for manufacturing
- Processed and analysed
- Returned for administration
This model places significant pressure on clinical supply chain management, particularly in ensuring end-to-end visibility, chain of custody, and real-time coordination across stakeholders.
There is no buffer. No excess stock. No room for delay.
Narrow treatment windows increase execution risk
In traditional trials, delays are often manageable. In CGT, they are not.
From the moment a therapy is ready, there may be only hours to deliver and administer it.
This creates a dependency on highly coordinated clinical trial logistics management and reliable Investigational Medicinal Product (IMP) distribution processes.
Delays go beyond operational impact — they can affect:
- Product viability
- Patient safety
- Clinical trial outcomes
This is where execution becomes critical to success.
Temperature sensitivity requires advanced cold chain control
Many cell and gene therapies must be maintained at ultra-low temperatures, often below -150°C.
This introduces significant complexity across:
- Cold chain distribution
- Clinical trial cold chain packaging
- Temperature controlled pharmaceutical storage
- Specialized cryogenic storage and cryostorage for cell therapies
Even minor deviations in temperature can compromise the integrity of the therapy.
As a result, cold chain pharmaceutical distribution, clinical trial cold chain packaging, and validated packaging solutions become essential components of the clinical trial supply chain.
Cross-border complexity increases regulatory pressure
CGT trials are rarely confined to a single geography.
Collection, manufacturing, and administration may take place in different countries, requiring coordination across:
- Clinical trial regulatory management
- Global regulatory strategy for pharmaceuticals
- Pharma supply chain compliance
- QP release for clinical trial products and QP batch release
Each stage must meet local and international pharmaceutical compliance and regulatory standards.
This increases the importance of:
- End-to-end visibility
- Regulatory expertise
- Consistent compliance in supply chain management
Without this alignment, trials can be delayed — or prevented from proceeding altogether.
Packaging and labeling are critical to compliance and delivery
In CGT trials, packaging and labeling are not administrative steps — they are integral to execution.
This includes:
- Clinical trial labeling and labeling compliance
- Secondary packaging and clinical secondary packaging
- All temperature package labeling and certified labeling solutions
- Clinical trial packaging and cold chain packaging solutions
Errors in labeling or packaging can lead to:
- Regulatory non-compliance
- Shipment delays
- Risk to patient safety
As a result, pharmaceutical packaging solutions must be designed specifically for the demands of CGT.
Execution is now the defining factor in clinical trial success
Each of these challenges is manageable in isolation.
But in combination, they create a level of complexity that traditional models were not designed to handle.
For cell and gene services providers, clinical operations teams, and supply chain leaders, this means:
- Planning must start earlier
- Supply chains must be designed around real-world constraints
- Partnerships must support integrated delivery
- Execution must be treated as a core capability, not a support function
As the number of CGT trials continues to grow, these pressures will only increase.
What this means for the future of clinical development
The clinical development model itself isn’t being replaced — but it’s evolving.
New approaches, including more integrated supply models and advanced data-driven coordination, are beginning to address some of today’s challenges.
However, the fundamental shift remains:
Success in CGT depends not only on scientific innovation, but on the ability to deliver therapies reliably, precisely, and at speed.
For many organizations, this requires a step change in how clinical trial logistics, supply chain management, and regulatory compliance are approached.
Because in this environment, execution is no longer a supporting function.
It’s the system that makes delivery possible — and ultimately determines whether a therapy reaches the patient.
